On July 22, Bruker rose 5.09% in regular trading, trading at $59.17 USD/share, with turnover of approximately $83.90 million. The rally was driven by the dual catalysts of a strategic acquisition and analyst upgrade.

On the news front, Bruker recently announced the acquisition of Noscendo's Disqver clinical metagenomics platform, expanding its next-generation sequencing-based infection detection portfolio. The Disqver platform enables rapid and comprehensive pathogen detection directly from patient blood samples, significantly improving diagnostic efficiency for critical infections such as sepsis. This marks an important strategic move in the precision diagnostics space.

Additionally, BofA Securities raised its price target on Bruker from $65 to $70, maintaining an Overweight rating — well above the market consensus target of $51.58, signaling strong institutional confidence. The company previously guided full-year revenue of $3.57B to $3.60B and adjusted EPS of $2.10 to $2.15, both in line with market expectations, providing fundamental support for valuation recovery.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)